BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31975315)

  • 1. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
    Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
    Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
    Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
    Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
    Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    Farias AJ; Wu WH; Du XL
    BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
    Farias AJ; Du XL
    Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
    [No Abstract]   [Full Text] [Related]  

  • 12. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
    Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
    Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
    Saraf A; Tahir I; Hu B; Dietrich AW; Tonnesen PE; Sharp GC; Tillman G; Roeland EJ; Nipp RD; Comander A; Peppercorn J; Fintelmann FJ; Jimenez RB
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):94-103. PubMed ID: 37506979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
    Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
    Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
    JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
    Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
    JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
    Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
    J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
    Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.